| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48.
|
| [2] |
Lumachi F, Brunello A, Maruzzo M, et al. Treatment of estrogen receptor-positive breast cancer [J]. Curr Med Chem, 2013, 20(5): 596-604.
|
| [3] |
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J]. JAMA, 2006, 295(21): 2492-2502.
|
| [4] |
Boland MR, Ryan ÉJ, Nugent T, et al. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients [J]. J Surg Oncol, 2020, 122(5): 861-868.
|
| [5] |
Kubo M. Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer [J]. Chin Clin Oncol, 2020, 9(3): 33.
|
| [6] |
Höller A, Nguyen-Sträuli BD, Frauchiger-Heuer H, et al. "Diagnostic and prognostic biomarkers of luminal breast cancer: where are we now？" [J]. Breast Cancer (Dove Med Press), 2023, 15: 525-540.
|
| [7] |
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017 [J]. Ann Oncol, 2017, 28(8): 1700-1712.
|
| [8] |
Stockwell S. Classics in oncology. George Thomas Beatson, M．D. (1848-1933) [J]. CA Cancer J Clin, 1983, 33(2): 105-121.
|
| [9] |
Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer [J]. Cancer Cell, 2020, 37(4): 496-513.
|
| [10] |
Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer [J]. N Engl J Med, 1981, 304(1): 16-21.
|
| [11] |
Waks AG, Winer EP. Breast cancer treatment: a review [J]. JAMA, 2019, 321(3): 288-300.
|
| [12] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)．Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 365(9472): 1687-1717.
|
| [13] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)．Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J]. Lancet, 2015, 386(10001): 1341-1352.
|
| [14] |
Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer [J]. N Engl J Med, 2010, 362(22): 2053-2065.
|
| [15] |
Pagani O, Francis PA, Fleming GF, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT [J]. J Clin Oncol, 2020, 38(12): 1293-1303.
|
| [16] |
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2019, 30(10): 1674.
|
| [17] |
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression [J]. J Clin Oncol, 2016, 34(14): 1689-1701.
|
| [18] |
Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J]. Lancet, 2011, 378(9793): 771-784.
|
| [19] |
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial [J]. Lancet Oncol, 2010, 11(12): 1135-1141.
|
| [20] |
Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [J]. N Engl J Med, 2005, 353(26): 2747-2757.
|
| [21] |
Van De Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial [J]. Lancet, 2011, 377(9762): 321-331.
|
| [22] |
Derks MGM, Blok EJ, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol, 2017, 18(9): 1211-1220.
|
| [23] |
Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen [J]. J Clin Oncol, 2010, 28(3): 509-518.
|
| [24] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J]. Lancet, 2013, 381(9869): 805-816.
|
| [25] |
Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J]. J Natl Cancer Inst, 1996, 88(21): 1529-1542.
|
| [26] |
Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group [J]. Br J Cancer, 1996, 74(2): 297-299.
|
| [27] |
Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group [J]. J Natl Cancer Inst, 1996, 88(24): 1828-1833.
|
| [28] |
Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update [J]. J Clin Oncol, 2014, 32(21): 2255-2269.
|
| [29] |
Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 [J]. J Natl Cancer Inst, 2005, 97(17): 1262-1271.
|
| [30] |
Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial [J]. J Clin Oncol, 2008, 26(12): 1965-1971.
|
| [31] |
Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a [J]. J Natl Cancer Inst, 2007, 99(24): 1845-1853.
|
| [32] |
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update [J]. J Clin Oncol, 2019, 37(5): 423-438.
|
| [33] |
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer [J]. J Natl Cancer Inst, 1997, 89(22): 1673-1682.
|
| [34] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)．Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100，000 women in 123 randomised trials [J]. Lancet, 2012, 379(9814): 432-444.
|
| [35] |
Rubens RD, Sexton S, Tong D, et al. Combined chemotherapy and radiotherapy for locally advanced breast cancer [J]. Eur J Cancer, 1980, 16(3): 351-356.
|
| [36] |
Clough KB, Acosta-Marín V, Nos C, et al. Rates of neoadjuvant chemotherapy and oncoplastic surgery for breast cancer surgery: a French national survey [J]. Ann Surg Oncol, 2015, 22(11): 3504-3511.
|
| [37] |
Vugts G, Maaskant-Braat AJ, Nieuwenhuijzen GA, et al. Patterns of care in the administration of neo-adjuvant chemotherapy for breast cancer. A population-based study [J]. Breast J, 2016, 22(3): 316-321.
|
| [38] |
Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States [J]. Cancer, 2015, 121(15): 2544-2552.
|
| [39] |
Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice [J]. Cancer Res, 1989, 49(8): 1996-2001.
|
| [40] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
|
| [41] |
Von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer [J]. J Clin Oncol, 2013, 31(29): 3623-3630.
|
| [42] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J]. Lancet Oncol, 2018, 19(1): 27-39.
|
| [43] |
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer [J]. N Engl J Med, 2004, 351(27): 2817-2826.
|
| [44] |
Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer [J]. Nat Rev Clin Oncol, 2017, 14(10): 595-610.
|
| [45] |
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer [J]. J Clin Oncol, 2006, 24(23): 3726-3734.
|
| [46] |
Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J]. Lancet Oncol, 2010, 11(1): 55-65.
|
| [47] |
Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials [J]. J Clin Oncol, 2008, 26(5): 721-728.
|
| [48] |
Van’T Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer [J]. Nature, 2002, 415(6871): 530-536.
|
| [49] |
Cardoso F, Van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer [J]. N Engl J Med, 2016, 375(8): 717-729.
|
| [50] |
Andre F, Ismaila N, Henry NL, et al. Use of Biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx [J]. J Clin Oncol, 2019, 37(22): 1956-1964.
|
| [51] |
Mcandrew NP, Finn RS. Management of ER positive metastatic breast cancer [J]. Semin Oncol, 2020, 47(5): 270-277.
|
| [52] |
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)? [J]. Ann Oncol, 2014, 25(10): 1871-1888.
|
| [53] |
Xu HB, Liu YJ, Li L. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis [J]. Clin Breast Cancer, 2011, 11(4): 246-251.
|
| [54] |
Mauri D, Pavlidis N, Polyzos NP, et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis [J]. J Natl Cancer Inst, 2006, 98(18): 1285-1291.
|
| [55] |
Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer [J]. Hematol Oncol Clin North Am, 2013, 27(4): 715-736; 715-736, viii.
|
| [56] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [J]. J Clin Oncol, 2010, 28(30): 4594-4600.
|
| [57] |
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer [J]. Nat Genet, 2013, 45(12): 1446-1451.
|
| [58] |
Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer [J]. Nat Rev Clin Oncol, 2015, 12(10): 573-583.
|
| [59] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer [J]. N Engl J Med, 2012, 366(6): 520-529.
|
| [60] |
Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2? [J]. Ann Oncol, 2014, 25(12): 2357-2362.
|
| [61] |
Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline [J]. J Clin Oncol, 2016, 34(25): 3069-3103.
|
| [62] |
Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials [J]. J Clin Oncol, 2001, 19(2): 343-353.
|
| [63] |
Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [J]. N Engl J Med, 2014, 371(2): 107-118.
|
| [64] |
Chun KH, Park JH, Fan S. Predicting and overcoming chemotherapeutic resistance in breast cancer [J]. Adv Exp Med Biol, 2017, 1026: 59-104.
|
| [65] |
Klinge CM. Estrogen receptor interaction with estrogen response elements [J]. Nucleic Acids Res, 2001, 29(14): 2905-2919.
|
| [66] |
Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription [J]. Curr Genomics, 2006, 7(8): 497-508.
|
| [67] |
Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer [J]. Breast Cancer, 2018, 25(4): 392-401.
|
| [68] |
Telang NT. The Divergent effects of ovarian steroid hormones in the MCF-7 model for luminal a breast cancer: mechanistic leads for therapy [J]. Int J Mol Sci, 2022, 23(9): 4800.
|
| [69] |
Van Der Spek YM, Kroep JR, Tollenaar R, et al. Chemotherapy resistance and stromal targets in breast cancer treatment: a review [J]. Mol Biol Rep, 2020, 47(10): 8169-8177.
|
| [70] |
Kumar U, Ardasheva A, Mahmud Z, et al. FOXA1 is a determinant of drug resistance in breast cancer cells [J]. Breast Cancer Res Treat, 2021, 186(2): 317-326.
|
| [71] |
Zeng J, Li G, Xia Y, et al. miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers [J]. Cancer Lett, 2020, 492: 185-196.
|
| [72] |
Tang H, Chen J, Wang L, et al. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer [J]. Int J Pharm, 2020, 573: 118 806.
|
| [73] |
Wang S, Lee D. Identifying prognostic subgroups of luminal-A breast cancer using deep autoencoders and gene expressions [J]. PLoS Comput Biol, 2023, 19(5): e1011197.
|
| [74] |
Yu D, Liu S, Chen Y, et al. Integrative bioinformatics analysis reveals CHEK1 and UBE2C as luminal A breast cancer subtype biomarkers [J]. Front Genet, 2022, 13: 944259.
|
| [75] |
Jia X, Lei H, Jiang X, et al. Identification of crucial lncRNAs for luminal A breast cancer through RNA sequencing [J]. Int J Endocrinol, 2022, 2022: 6577942.
|
| [76] |
Ahn S, Kwon A, Huh YH, et al. Tumor-derived miR-130b-3p induces cancer-associated fibroblast activation by targeting SPIN90 in luminal A breast cancer [J]. Oncogenesis, 2022, 11(1): 47.
|